OTCMKTS:GNMLF Genomma Lab Internacional (GNMLF) Stock Price, News & Analysis $0.72 0.00 (0.00%) As of 10/28/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Genomma Lab Internacional Stock (OTCMKTS:GNMLF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GNMLF alerts:Sign Up Key Stats Today's Range$0.72▼$0.7250-Day Range$0.69▼$0.8352-Week Range$0.69▼$1.08VolumeN/AAverage Volume22,825 shsMarket CapitalizationN/AP/E Ratio0.42Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Genomma Lab Internacional, S.A.B. de C.V. (OTCMKTS: GNMLF) is a Mexico-based consumer healthcare and personal care company. It develops, markets and distributes over-the-counter medicines, medical devices, cosmetics and hygiene products, primarily through retail pharmacies, supermarkets and other consumer channels. The company’s portfolio includes products for areas such as pain relief, respiratory health, gastrointestinal care, dermatology, hair care and skin care. Its recognized brands include Asepxia, Cicatricure, Goicoechea, Tío Nacho, Silka and Next, although product availability varies by market. Genomma Lab was established in Mexico in 1996 and has expanded its operations across Latin America, with a presence that has included markets such as Argentina, Brazil, Chile, Colombia, Ecuador and Peru, as well as the United States. The company is headquartered in Mexico City and is listed on the Mexican Stock Exchange under the symbol LAB.AI Generated. May Contain Errors. Read More Genomma Lab Internacional Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreGNMLF MarketRank™: 0.454838709675 of 5 starsGenomma Lab Internacional scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingGenomma Lab Internacional has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGenomma Lab Internacional has received no research coverage in the past 90 days.Read more about Genomma Lab Internacional's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genomma Lab Internacional is 0.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Genomma Lab Internacional is 0.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 37.18. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverGenomma Lab Internacional has a short interest ratio ("days to cover") of 417.85, which indicates bearish sentiment.Change versus previous monthShort interest in Genomma Lab Internacional has recently decreased by 20.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenomma Lab Internacional does not currently pay a dividend.Dividend GrowthGenomma Lab Internacional does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genomma Lab Internacional insiders have not sold or bought any company stock.Percentage Held by Institutions36.55% of the stock of Genomma Lab Internacional is held by institutions.Read more about Genomma Lab Internacional's insider trading history. Receive GNMLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genomma Lab Internacional and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNMLF Stock News HeadlinesGenomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q3 2026 Earnings Call TranscriptOctober 22, 2026 | seekingalpha.comGenomma Lab Internacional Announces Results for the Third Quarter 2026October 21, 2026 | prnewswire.comElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding two or three asymmetric home runs. Analyst Jeff Brown says he has identified a new one, a single stock he calls Elon Musk's One Stock Retirement Plan.October 29 at 1:00 AM | Brownstone Research (Ad)Genomma Lab Internacional SAB de CV (GNMLF) Q2 2026 Earnings Call Highlights: Navigating Market ...July 25, 2026 | finance.yahoo.comGenomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q2 2026 Earnings Call TranscriptJuly 24, 2026 | seekingalpha.comGenomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q1 2026 Earnings Call TranscriptApril 23, 2026 | seekingalpha.comGenomma Lab Internacional Announces Results for the First Quarter 2026April 22, 2026 | prnewswire.comGenomma Lab Internacional S.A.B. de C.V. First Quarter 2026 Earnings Results Conference CallApril 13, 2026 | prnewswire.comSee More Headlines GNMLF Stock Analysis - Frequently Asked Questions How have GNMLF shares performed this year? Genomma Lab Internacional's stock was trading at $1.06 at the start of the year. Since then, GNMLF stock has decreased by 31.9% and is now trading at $0.7222. How do I buy shares of Genomma Lab Internacional? Shares of GNMLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:GNMLF CIKN/A Webwww.genommalab.com Phone525550810000FaxN/AEmployees1,465Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.42 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:GNMLF) was last updated on 10/28/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genomma Lab Internacional, S.A.B. de C.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genomma Lab Internacional With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.